So sánh phương pháp
Xem các phương pháp đã chọn cạnh nhau; những hàng khác biệt được làm nổi bật.
| Bảng câu hỏi về Trí nhớ Tiên liệu và Hồi tưởng× | Thang đo Đánh giá Bệnh Alzheimer – Nhận thức× | |
|---|---|---|
| Lĩnh vực | Tâm lý học thần kinh | Tâm lý học thần kinh |
| Họ | Process / pipeline | Process / pipeline |
| Năm ra đời≠ | 2003 | 1984 |
| Người khởi xướng≠ | John Crawford | William Rosen |
| Loại≠ | Self-report questionnaire of prospective and retrospective memory complaints | Clinician-administered cognitive scale for Alzheimer's disease |
| Công trình gốc≠ | Crawford, J. R., Smith, G., Maylor, E. A., Della Sala, S., & Logie, R. H. (2003). The Prospective and Retrospective Memory Questionnaire (PRMQ): Normative data and latent structure in a large non-clinical sample. Memory, 11(3), 261-275. DOI ↗ | Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141(11), 1356-1364. DOI ↗ |
| Tên gọi khác≠ | PRMQ, Prospective Retrospective Memory Questionnaire | ADAS-Cog, ADAS-Cog14, ADAS-Cog13 |
| Liên quan | 5 | 5 |
| Tóm tắt≠ | The Prospective and Retrospective Memory Questionnaire (PRMQ) is a 16-item self-report instrument designed to measure subjective memory complaints across two distinct memory domains: prospective memory (remembering to do things in the future) and retrospective memory (remembering past events and information). Developed by Crawford and colleagues at the University of Edinburgh in 2003, the PRMQ provides a brief, validated tool for assessing everyday memory lapses and their impact on functional well-being in both clinical and non-clinical populations. | The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) is a clinician-administered cognitive assessment instrument designed specifically to measure cognitive decline in Alzheimer's disease. Developed by Rosen, Mohs, and Davis in 1984 and published in the American Journal of Psychiatry, the ADAS-Cog has become the gold standard outcome measure in pharmaceutical trials of antidementia drugs. It is sensitive to disease progression and capable of detecting cognitive change over periods as brief as 6–12 months. |
| ScholarGateBộ dữ liệu ↗ |
|
|